Emgality
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Galcanezumab
- Made by
- Eli Lilly Nederland B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Eli Lilly Nederland B.V. |
|---|---|
| Active substance | Galcanezumab |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N02 · Pain, sleep, mood, epilepsy and the brain |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2018-11-14 |
| Last updated by the regulator | 2026-09-11 |
| EMA product number | EMEA/H/C/004648 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).